Pacific Biosciences of California, Inc.
|$288 M||Market Cap|
|N/A||EBIT / EV|
|N/A||FCF / EV|
|18.0%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Cannot calculate EBIT / Enterprise Value, company has negative EBIT.|
|Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.|
|Cannot calculate Return on Invested Capital, company has negative EBIT.|
|Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.|
|The 3 Year Average Revenue Growth Value of 18.0% ranks as Above Average.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 4.68.|
Pacific Biosciences of California, Inc. engages in the research, development and manufacture of sequencing systems for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia. It offers deoxyribonucleic acid sequencing, third generation sequencing instrument, compatible workflow and analysis, resequencing and variant detection, epigenetics, multiplexing, sample and template preparation kits, binding kits, and sequel software applications. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
|Exelixis, Inc. (EXEL)|
|Appian Corporation Class A (APPN)|
|AppFolio Inc Class A (APPF)|
|Hershey Company (HSY)|
|Harley-Davidson, Inc. (HOG)|